Pfizer (PFE) and BioNTech (BNTX) said in a statement: “COVID-19 has transitioned from a pandemic to an endemic disease. Even so, COVID-19 disease still hospitalizes hundreds of thousands of Americans and is responsible for the death of thousands every year. Pfizer and BioNTech remain deeply committed to making safe and effective vaccines that help protect lives in the U.S. and around the world. The Pfizer-BioNTech COVID-19 vaccine has been reviewed by multiple regulatory authorities, including the FDA, and has met all safety and quality control guidelines…In summary, Pfizer and BioNTech remain steadfast in our dedication to vaccine safety, quality and effectiveness through constant safety monitoring and ongoing research. With 5 billion doses distributed to date globally and continued approval by regulatory agencies in 83 countries, our vaccines are among the most extensively monitored products licensed in the world-helping prevent hospitalizations and saving lives.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says
- Mixed options sentiment in Pfizer with shares up 0.48%
- Arvinas price target lowered to $14 from $16 at Stephens
- Arvinas, Pfizer to out-license commercialization rights to vepdegestrant
- Moderately bullish activity in Pfizer with shares up 1.07%
